Núcleo de Pós-Graduação e Pesquisa, Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil.
J Clin Pharmacol. 2013 Oct;53(10):1072-7. doi: 10.1002/jcph.146. Epub 2013 Aug 1.
Statins exert cholesterol-independent beneficial effects on multiple targets including the cardiovascular system, in addition to modulating matrix metalloproteinases (MMPs) expression. The purpose of this study was to assess the effects of simvastatin treatment in obese women without comorbidities. We recruited 33 obese women that received placebo or simvastatin at 20 mg/day for 45 days. Plasma MMP-9, MMP-2, TIMP-1, and TIMP-2 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Cardiovascular risk was assessed by the Framingham risk score and Castelli indexes I and II. Treatment with simvastatin significantly reduced MMP-9 levels and the MMP-9/TIMP-1 ratio (P < .05) when compared to the placebo group (P > .05). Conversely, we found no effect on MMP-2, TIMP-1, and TIMP-2 levels or on the MMP-2/TIMP-2 ratio (P > .05). The Framingham risk score and Castelli I and II indexes were significantly reduced in the simvastatin-treatment group (P < .05), while we found no effect on the placebo group. These findings may have clinical importance since simvastatin therapy reduced cardiovascular risk and MMP-9 levels in obese woman without comorbidities, indicating a potentially new therapeutic approach.
他汀类药物除了调节基质金属蛋白酶（MMPs）表达外，还对心血管系统等多个靶点发挥胆固醇非依赖性的有益作用。本研究旨在评估辛伐他汀治疗无合并症肥胖女性的效果。我们招募了 33 名肥胖女性，她们每天接受安慰剂或辛伐他汀 20mg 治疗 45 天。使用酶联免疫吸附测定（ELISA）法测量血浆 MMP-9、MMP-2、TIMP-1 和 TIMP-2 水平。通过 Framingham 风险评分和 Castelli 指数 I 和 II 评估心血管风险。与安慰剂组相比，辛伐他汀治疗组 MMP-9 水平和 MMP-9/TIMP-1 比值显著降低（P<.05）（P>.05）。相反，我们发现 MMP-2、TIMP-1 和 TIMP-2 水平或 MMP-2/TIMP-2 比值没有影响（P>.05）。辛伐他汀治疗组的 Framingham 风险评分和 Castelli I 和 II 指数显著降低（P<.05），而安慰剂组则没有影响。这些发现可能具有临床意义，因为辛伐他汀治疗可降低无合并症肥胖女性的心血管风险和 MMP-9 水平，表明这是一种潜在的新治疗方法。
